Ligand News and Research

RSS

Immune checkpoint molecule protects against future development of cancer

A research team at the University of Louisville has discovered that an immune checkpoint molecule they developed for cancer immunotherapy, also protects against future development of multiple types of cancer when administered by itself.

15 Feb 2019

Novel approach uses small amounts of tissue to quantify PD-L1 expression levels in tumors

Immune checkpoint inhibitors, such as the anti-PD-1 antibody pembrolizumab, have become important tools for managing non-small-cell lung cancer.

14 Feb 2019

Newly discovered molecules show potential to treat obesity and fatty liver disease

Amiram Goldblum and his team at the Hebrew University of Jerusalem's Institute for Drug Research have discovered 27 new molecules. These molecules all activate a special protein called PPAR-delta and have the potential to treat fatty liver disease, obesity, diabetic nephrotoxicity, and to heal wounds.

31 Jan 2019

Researchers create synthetic growth factor that offers comparable biological response

Growth factors are ligands that play important roles in the body - they are responsible for tissue regeneration, wound healing, and the maintenance and growth of cells.

28 Jan 2019

Scientists use integrative approach to study how COQ9 binds and interacts with lipids

The synthesis and transport of biological lipids across the mostly water-filled interior of the cell is a longstanding problem in biology.

28 Jan 2019

Ural Federal University scientists synthesize a group of multi-purpose fluorophores

A group of scientists from Russia's Ural Federal University, headed by Professor Grigory Zyryanov, synthesized a group of multi-purpose fluorophores.

18 Jan 2019

Novel targeted drug delivery system improves conventional cancer treatments

A team of researchers, affiliated with UNIST has recently introduced a novel targeted drug delivery system that can improve the pharmacological and therapeutic properties of conventional cancer treatments.

17 Jan 2019

Scientists identify endogenous activator of sigma-1 receptors in human cells

Cells communicate through complex mechanisms that typically involve receptors and ligands that bind to them. Endogenous ligands, produced by the body, have been identified for the vast majority of cellular receptors, helping explain receptor existence and function. But in the case of sigma-1 receptors, which interact with a diverse array of psychoactive drugs, an endogenous ligand has remained elusive.

14 Jan 2019

New potential immunotherapy target in pancreatic cancer identified

Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers.

11 Jan 2019

Bio-Rad publishes new paper on generation, characterization of complex-specific antibodies

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, has published new findings on the generation and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.

From Bio-Rad Laboratories 11 Jan 2019

A small protein plays key role in how cancer stem cells differentiate

A jagged little protein appears to be key to how cancer stem cells differentiate and enable metastasis, according to researchers at Rice University and the Duke University School of Medicine.

4 Jan 2019

Developing the Next Generation of Water-soluble DREADDs

An interview with James Flanaghan, discussing the uses of DREADDs in neurobiological research and the advantages of water-soluble ligands.

From Hello Bio 19 Dec 2018

New mouse model shows potential for rapid identification of promising muscular dystrophy therapies

A Massachusetts General Hospital research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful.

13 Dec 2018

Findings may open up new ways to treat dwarfism and other ER-stress-related conditions

Pseudoachondroplasia (PSACH) is a severe inherited dwarfing condition characterized by disproportionate short stature, joint laxity, pain, and early onset osteoarthritis.

12 Dec 2018

ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients

Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse array of topics to be discussed at the ESMO Immuno-Oncology Congress, to be held 13-16 December in Geneva, Switzerland.

11 Dec 2018

From Our Bench to Yours: Antibody Advice from Proteintech

An interview with Dr. Karolina Szczesna, discussing the tell-tale signs of a good antibody and how Proteintech are working to improve experimental results for scientists.

From Proteintech Group, Inc 5 Dec 2018

Researchers find crucial inhibitory role for signal peptide in GluK1 trafficking

Glutamate is the major excitatory neurotransmitter in the brain, and the postsynaptic expression level of glutamate receptors is a critical factor in determining the efficiency of information transmission and the activity of the neuronal network.

19 Nov 2018

Study finds kill code mechanism embedded in every cell to extinguish cancer

A kill code is embedded in every cell in the body whose function may be to cause the self-destruction of cells that become cancerous, reports a new Northwestern Medicine study. As soon as the cell's inner bodyguards sense it is mutating into cancer, they punch in the kill code to extinguish the mutating cell.

29 Oct 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor, axitinib, significantly improves progression-free survival in previously untreated patients with advanced renal cell carcinoma in a phase 3 study, according to results presented at ESMO 2018 Congress.